1. Introduction {#sec1-jcm-09-01481}
===============

Atrial fibrillation (AF) is one of the most common cardiovascular (CV) diseases worldwide, with an increasing global burden associated with the ageing of the population. AF frequently occurs in patients with acute myocardial infarction (AMI), with an incidence ranging from 6% to 21% \[[@B1-jcm-09-01481]\], and is associated with an increased risk of death and rehospitalisation for heart failure, which in turn have major economic consequences \[[@B2-jcm-09-01481]\]. AF leads to atrial remodeling through an alteration of the electrical and structural properties of the atria, thus facilitating the maintenance and recurrence of AF \[[@B3-jcm-09-01481]\]. Several risk factors for AF have already been identified in various populations, but the predictive power of individual risk factors is still far from accurate. Heart rate variability (HRV), measured by Holter-ECG, reflects cardiovascular response to the autonomic nervous system (ANS) and altered (reduced or enhanced) HRV may have a major role in the onset of AF in AMI patients with coronary artery disease (CAD) \[[@B4-jcm-09-01481]\]. However, in the setting of AMI, the role of the ANS is uncertain and data are scarce \[[@B5-jcm-09-01481]\]. The aim of this retrospective analysis of a large database of patients was to evaluate whether autonomic dysfunction (measured by HRV) could be associated with new-onset AF in AMI: is it an epiphenomenon related to sympathetic activation linked to the severity of the infarction, or is it related to parasympathetic dependence which would suggest chronic electrical and anatomical atrial remodeling and therefore risk of recurrence?

2. Experimental Section {#sec2-jcm-09-01481}
=======================

2.1. Patients {#sec2dot1-jcm-09-01481}
-------------

The participants were recruited from the RICO (obseRvatoire des Infarctus de Côte-d'Or) database, a regional registry for cases of acute myocardial infarction (MI). Briefly, RICO collects data from all patients hospitalized for acute MI in all public or privately funded hospitals of one department in the east of France \[[@B6-jcm-09-01481]\]. The present study included all consecutive patients admitted between 20th June 2001 and 2nd November 2014 (\>18 years old) who underwent a 24-h Holter ECG recording during their coronary care unit stay. Patients with a history of AF (n = 94) were excluded, we checked for each patient admission his/her previous medical history, baseline treatments and medical recording in the hospital files. In case of suspicion of previous AF that cannot be confirmed by the patient (anticoagulant therapy, antiarrhythmic drug) we systematically called the general practitioner or the cardiologist of the patient to explain this drug prescriptions. A flow chart reporting the inclusion and exclusion criteria is shown in [Figure 1](#jcm-09-01481-f001){ref-type="fig"}. The present study complied with the Declaration of Helsinki and was approved by the ethics committee of the University Hospital of Dijon. Each patient provided written consent before participation.

2.2. Data Collection {#sec2dot2-jcm-09-01481}
--------------------

Patient data were collected from the RICO database: continuous electrocardiographic monitoring (CEM) data (rhythm status during AMI), cardiovascular risk factors, clinical data, type of AMI, acute management, acute and discharge medications, biological data, echocardiography data including LVEF (with a cut-off at 40% using Simpson's method for more clinical relevance) and left atrial dimensions as previously described \[[@B7-jcm-09-01481]\].

2.3. AF Definition {#sec2dot3-jcm-09-01481}
------------------

AF was diagnosed in accordance with the current European Society of Cardiology Guidelines as absolutely irregular RR intervals and no discernible, distinct P waves and an episode duration of at least 30 s. Flutter episodes were included as AF episodes \[[@B8-jcm-09-01481]\].

2.4. Biological Data {#sec2dot4-jcm-09-01481}
--------------------

Blood samples were drawn on admission. Plasma creatinine levels were measured on a Vitros 950 analyzer (Ortho Clinical Diagnostics, Rochester, New York, USA). Glomerular filtration rate was calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. C-reactive protein (CRP) was determined on a dimension Xpand (Dade Behring, Deerfield, Illinois, USA) using enzymatic methods. CRP level was dichotomized into high and low categories at 3 mg/L for more clinical relevance.

2.5. Holter ECG Data {#sec2dot5-jcm-09-01481}
--------------------

If the patient consented to undergo a 24-h (Holter) ECG, it was done in the coronary care unit within the 24 h following admission. Holter monitoring was based on device availability \[[@B6-jcm-09-01481]\], patient consent and expected hospital stay \>48 h within our cardiology department to be able to obtain Holter results before hospital discharge. Long ECG tracing was recorded and analyzed by two experienced observers using a Syneflash digital recorder Holter (Ela medical and Spieder Viers, le Plessis Robinson, France), with seven surface electrode signals (acquisition sampling rate: 1000 Hz). After classifying the QRS morphology, the RR intervals (longest and shortest) were confirmed manually until no QRS sequences were incorrectly labelled. Only sequences with normal QRS characteristics during 24 h (sinus rhythm) were analysed for HRV study. HRV was addressed from the time or frequency domain in accordance with the 1996 guidelines of the ESC Task Force \[[@B9-jcm-09-01481]\]: Time domain variables: (1) rMSSD: root mean square of successive differences in NN intervals is considered an estimate of the short-term components of HRV, which correspond to parasympathetic activity. (2) pNN50: proportion derived by dividing NN50 (the number of interval differences of successive NN intervals greater than 50 ms) by the total number of NN intervals. This is a measure of parasympathetic activity. (3) SDNN: the standard deviation of all intervals between adjacent QRS complexes resulting from sinus node depolarization (NN), i.e., the square root of variance, reflects the cyclic components responsible for variability in the period of recording and is considered as an estimate of overall HRV, encompassing vagal and sympathetic influences \[[@B10-jcm-09-01481],[@B11-jcm-09-01481]\].

Frequency domain variables: Fast Fourier transform was used to convert the different successive RR intervals in the frequency domain. Low frequencies (LF), between 0.04 and 0.15 Hz, are affected by both vagal and sympathetic activity, whereas high frequencies (HF), between 0.15 and 0.4 Hz, are affected by vagal tone. The LF/HF ratio is therefore considered an indicator of sympathovagal balance; oscillations in very low frequencies VLF (range 0.00 to 0.04 Hz) reflect peripheral vasomotor regulation. Total power (TP), combining the sum of all the frequencies, is a global measure of ANS activity \[[@B10-jcm-09-01481],[@B11-jcm-09-01481]\].

2.6. Statistical Analyses {#sec2dot6-jcm-09-01481}
-------------------------

Results were expressed as medians \[IQR\] for continuous variables and as percentages for dichotomized variables. Normality was tested with the Kolmogorov-Smirnov test. For continuous data, we used the Mann-Whitney test. Categorical variables were compared with the χ^2^ or Fisher exact test. A p value of less than 0.05 was considered statistically significant. Since the NT-proBNP values do not follow a normal distribution, a logarithmic transformation was performed. To assess discrimination for AF recurrences, we examined the area under the receiver-operating characteristic (ROC) curve (plot of sensitivity versus 1---specificity for all possible cut-off values to classify predictions) for the LF-HF with the best sensitivity, specificity, positive predictive value and negative predictive value according to the Youden index. Multivariate logistic regression models were built to estimate the odds ratio (OR) of in-hospital AF and of a LF/HF ratio cut-off value. Variables that met the statistical significance threshold of 5% in univariable analysis were included in the multivariate models. LVEF was not included in the final model because of collinearity with NT-proBNP. To improve the robustness of results, the AF patients were matched 1:1 with the SR patients using nearest neighbor matching on the linear propensity score with a tolerance of 0.02. The same logistic regression model was used to compare AF with SR patients. The statistical tests were performed with SPSS software version 26 (IBM Corp., Armonk, NY, USA).

3. Results {#sec3-jcm-09-01481}
==========

3.1. Patient Characteristics {#sec3dot1-jcm-09-01481}
----------------------------

Of the 14,270 patients in the RICO database, 2040 (14.3%) met the main inclusion criteria of having a 24-h Holter ECG recording and no prior AF ([Figure 1](#jcm-09-01481-f001){ref-type="fig"}).

AF was identified in 168 (8.2%) of the included patients. [Table 1](#jcm-09-01481-t001){ref-type="table"}, [Table 2](#jcm-09-01481-t002){ref-type="table"}, [Table 3](#jcm-09-01481-t003){ref-type="table"} and [Table 4](#jcm-09-01481-t004){ref-type="table"} summarize the characteristics of the study population.

Patients from the AF group were almost 10 y older (77 vs. 64 y; *p* \< 0.001), more frequently hypertensive (68% vs 49%; *p* \< 0.001) and less likely to smoke (15% vs. 35%; *p* \< 0.001) then the rest of the study population. The pNN50 values of the AF group were almost thrice higher (11% vs. 4%; *p* \< 0.001), their rMSSD values were higher (45 vs. 27 ms; *p* \< 0.001) and the HR by Holter ECG was faster (73 vs. 66 beats/min; *p* \< 0.001). More AF patients had a LF/HF ratio \< 1.735% (75% vs. 30%; *p* \< 0.001). High creatinine (98 vs. 87 μmol/L; *p* \< 0.001), glycaemia (7.92 vs. 7.00 mmol/L; *p* \< 0.001) and NT-proBNP levels (2450 vs. 542 pg/mL; *p* \< 0.001) were observed in AF patients. They were also more likely to have a history of cardiovascular disease, including CAD, stroke, and renal failure. Accordingly, they were more likely to be taking chronic CV medications such as beta blockers and amiodarone (medication used for a history of ventricular arrhythmia (no atrial fibrillation ECG traces in their medical records)). The other admission parameters (including diabetes, time to admission, and troponin Ic peak) were not significantly different except for multivessel disease.

3.2. ROC Curve {#sec3dot2-jcm-09-01481}
--------------

The optimal cut-offs for continuous test variables were determined from the ROC curve, which was used to estimate the optimal threshold value of LF-HF. The best LF/HF value to characterize our population according to AF occurrence was a LF/HF ratio \<1.735, with an AUC of 0.73 (95% CI (0.69--0.78); *p* \< 0.001), sensitivity of 69% and specificity of 70% ([Figure 2](#jcm-09-01481-f002){ref-type="fig"}).

3.3. LF/HF Determinants: Multivariate Analysis {#sec3dot3-jcm-09-01481}
----------------------------------------------

In multivariate analysis, only age, female sex and diabetes were associated with low LF/HF, therefore excluding the influence of treatments such as beta blockers or the severity of AMI on this ANS parameter.

3.4. AF Determinants in Acute Myocardial Infarction {#sec3dot4-jcm-09-01481}
---------------------------------------------------

In univariate analysis ([Table 5](#jcm-09-01481-t005){ref-type="table"}) the risk factors for developing AF in the acute phase of infarction were: female sex, age, hypertension, smoking HR on Holter, CRP \> 3 mg/L, eGFR, log-NTproBNP, chronic use of ARB/ACE inhibitors and chronic use of beta-blockers.

In multivariate analysis, the independent risk factors for developing AF were age (OR 1.05 (1.03--1.07); *p* \< 0.001), HR (OR 1.04 (1.02--1.05); *p* \< 0.001) and log NT-proBNP (OR: 1.48(1.10--1.99, *p* = 0.010)) with a good predictive performance.

The addition of the LF/HF \< 1.735 variable significantly improved our ability to predict in-hospital AF (OR 3.38 (2.05--5.57); *p* \< 0.001).

Moreover, after 1:1 propensity score matching (on age, sex, previous hypertension, previous stroke, BMI, LVEF), LF/HF ratio \<1.735 (OR 3.49 (2.03--5.99), *p* \< 0.001) remained independently associated with the new-onset of AF during AMI.

3.5. Echocardiographic Parameters of Left Atrium {#sec3dot5-jcm-09-01481}
------------------------------------------------

We performed a subgroup analysis using left atrial (LA) echocardiographic parameters in patients for whom these parameters were available (n = 121 for LA diameter, 117 for LA area and n = 100 for LA volume). We started by conducting a univariate analysis to identify the LA size variable that could most powerfully predict AF. Next, we added the variable to a bivariate model and observed whether LF/HF remained independently associated with AF after adjustment on left atrial size. In univariate analysis, the only LA size parameter that was a predictor of in-hospital AF was LA volume (OR 1.03 (1.00--1.05); *p* \< 0.001). Among the patients included in the subgroup analysis, eight had a new-onset of AF during AMI. However, after bivariate analysis, neither LA volume nor LH/HF remained significantly associated with AF (*p* = 0.062 for both variables). Collinearity between the variables was not significant (variation inflation factor = 1.07).

4. Discussion {#sec4-jcm-09-01481}
=============

The results of our large, population-based study indicate that a low LF/HF (\<1.735) ratio was strongly associated with new-onset AF during AMI. Indeed, investigation of the median LF/HF ratio revealed that the sinus rhythm group and the AF group had a marked difference in sympathovagal balance. In our population, 75% of AF patients had a LF/HF ratio \< 1.735, compared to 30% of patients in the sinus rhythm group. Lower values of LF/HF ratio are thought to reflect decreased sympathetic activity and/or increased parasympathetic activity, i.e., above all, an imbalance of this sympathovagal tone.

4.1. AF in Acute Myocardial Infarction {#sec4dot1-jcm-09-01481}
--------------------------------------

It is still not known whether AF in AMI is promoted by acute activation of the sympathetic nervous system and is therefore a reversible arrhythmia, or if it occurs on a pre-existing atrial substrate that is prone to chronic dysregulation of ANS, indicating potential recurrence. This question is of particular interest considering the potential therapeutic consequences, particularly the initiation of oral anticoagulation therapy on top of the dual antiplatelet treatment prescribed to AMI patients. The role of autonomic tone in the genesis of atrial arrhythmia has been clinically recognized for many years, but autonomic modulation is extremely complex to characterize and quantify \[[@B4-jcm-09-01481]\]. In clinical cardiology, the main tool to evaluate ANS activity is the analysis of HRV parameters on continuous ECG recordings \[[@B9-jcm-09-01481]\]. The frequency-domain HRV parameters obtained by spectral analysis are considered the most useful parameters for addressing the sympathetic/parasympathetic balance. The HF components are thought to primarily reflect vagal tone, whereas the more complex LF components probably reflect sympathetic activity \[[@B4-jcm-09-01481]\]. Both the parasympathetic and the sympathetic nervous systems have been shown to play a role in AF. Amar et al., showed that the onset of AF was preceded by a primary increase in the sympathetic drive, followed by marked modulation toward vagal predominance \[[@B12-jcm-09-01481]\]. Our results suggest that there appears to be an ANS dysregulation prior to AMI, resulting in a paradoxical ANS response on the parasympathetic side where we would have expected an over-expression of the sympathetic system only.

4.2. LF/HF Ratio Findings {#sec4dot2-jcm-09-01481}
-------------------------

The ANS plays a central pathophysiological role in the initiation and progression of AF \[[@B13-jcm-09-01481]\]. Power spectral analysis of the beat-to-beat variations of heart rate or the heart period (R--R interval) has become widely used to quantify cardiac autonomic regulation. This technique partitions the total variance (the "power") of a continuous series of beats into its frequency components, typically identifying two main peaks: low frequency (LF), 0.04--0.15 Hz, and high frequency (HF) 0.15--0.4 Hz \[[@B9-jcm-09-01481]\]. The HF peak is widely believed to reflect cardiac parasympathetic nerve activity while the LF, although more complex, is often assumed to have a dominant sympathetic component. Based upon these assumptions, Pagani and colleagues suggested that the ratio of LF to HF (LF/HF) could be used to quantify the changing relationship between sympathetic and parasympathetic nerve activities (i.e., the sympathovagal balance) in both healthy and diseased organisms \[[@B14-jcm-09-01481]\]. The clinical determinants influencing HRV values were evaluated from Framingham's study, which showed that age and HR were the two main determinants of HRV in healthy subjects, in addition to sex and smoking \[[@B15-jcm-09-01481]\]. The LF/HF ratio has gained wide acceptance as a tool for assessing cardiovascular autonomic regulation where increases in LF/HF are assumed to reflect a shift towards "sympathetic dominance" and decreases indicate "parasympathetic dominance" \[[@B9-jcm-09-01481]\]. Moreover, it has been proved that non-linearity of neural modulation of cycle length may result in an intrinsic rate-dependency of autonomic indexes, with the exception of normalized frequency-domain indexes (like LF/HF), which appear to be devoid of intrinsic rate-dependency \[[@B16-jcm-09-01481]\]. Thus, LF/HF ratio is considered the more appropriate to assess ANS independently of heart rate and was also the most powerful predictor of AF in our results. The intrinsic rate-independency of LF/HF is very important: indeed, in our study, heart rate at admission was also associated with new-onset AF on top of LF/HF.

4.3. AF Determinants in Acute Myocardial Infarction {#sec4dot3-jcm-09-01481}
---------------------------------------------------

The present findings also confirm the significance of several known clinical risk factors, such as age, CAD, blood pressure and heart rate for the development of AF. We found that, after adjustment, only age, HR on Holter recording, and LF/HF ratio remained significant predictors of AF. Indeed, our results show that patients with low a LF/HF ratio are three times more likely to develop AF than patients with a higher LF/HF ratio (OR 3.65 (2.20--0.76; *p* \< 0.001)). The addition of LF/HF ratio to the classical AF predictors improved the diagnostic performance of the model, indicating that the parameters of the ANS are not fully covered by the classical clinical and biological predictors of AF during AMI. It therefore seems important to include this variable in existing risk scores. ANS plays an independent role on top of the variables classically used to predict AF, particularly on the parasympathetic side with a decrease in the LF/HF ratio. In addition, the other Holter ECG parameters used to evaluate parasympathetic activity, such as PNN50 or rMSSD, were consistent with our main hypothesis \[[@B9-jcm-09-01481]\]. In our population, the AF group had higher PNN50 and rMSSD values, stressing the importance of the parasympathetic component as an AF substrate. This result has led us to speculate that an underlying chronic disease may have preceded the onset of AMI. Indeed, some authors have shown that parasympathetic tone is increased by expansion and atrial fibrosis in experimental models of AF \[[@B17-jcm-09-01481]\]. In heart failure models, there is also an increase in sympathetic, parasympathetic and lymph node fibers in the left atrium that promote the maintenance and upkeep of arrhythmia \[[@B18-jcm-09-01481]\]. These results are strong evidence that parasympathetic activation is related to the electrical remodeling of the LA through myocyte remodeling, and that parasympathetic activation occurs before the AMI \[[@B19-jcm-09-01481]\]. Non-invasive measures obtained from Holter monitoring could identify an increased risk of AF in patients hospitalized for AMI, and could justify prolonged rhythm monitoring in patients identified as at-risk \[[@B20-jcm-09-01481]\]. Moreover, in addition to AF prediction, HRV data on scopes could improve the stratification of ventricular rhythmic risk, as previously shown \[[@B21-jcm-09-01481]\]. Consequently, we suggest that systematic and automated analysis of HRV data be added to the management of patients in the acute phase of MI. The contribution of LF/HF ratio to the prediction of AF recurrence risk at distance from the acute episode remains to be determined, but it may prove to be a useful tool for differentiating between acute AF episodes resulting from AMI and AF linked to pre-existing conditions at a high risk of recurrence \[[@B7-jcm-09-01481]\].

4.4. Limitations {#sec4dot4-jcm-09-01481}
----------------

Among the 14,270 patients included in the RICO registry, 12,136 (85.0%) were excluded due to a lack of Holter monitoring. This could lead to a selection bias, considering that only patients for whom the hospital stay was scheduled to be \>48h within our cardiology department were eligible to receive a Holter monitor, and this was also according to device availability. However, the large sample size of our included population, as well as the baseline characteristics that are close to the usual data obtained from the whole registry population in terms of age, CV risk factors and AMI type, should reduce this bias \[[@B22-jcm-09-01481]\].

We were not able to provide the dimensions of LA for all patients, which is unfortunate seeing as these parameters are known to be associated with the onset of AF. In the subgroup of patients for whom LA parameters were available, we found that LA volume and LF/HF ratio were not collinear variables. This result suggests that the predictive value of LF/HF ratio on new-onset AF in the whole population is not likely to be related to a statistical relationship between the ANS and LA dimensions' parameters.

Moreover, we can not exclude that new-onset AF patients had previous asymptomatic paroxysmal AF episodes (silent atrial fibrillation). However, we carefully checked patients medical history at admission to exclude previously known AF \[[@B3-jcm-09-01481]\].

5. Conclusions {#sec5-jcm-09-01481}
==============

The results of our large HRV analysis indicate that autonomic dysregulation is strongly associated with new-onset AF in AMI. It would appear that AF in AMI is not related to an acute sympathetic activation, but rather on a parasympathetic one, suggesting the presence of chronically impaired cardiac autonomic regulation in patients who experience such events. However, in the absence of direct assessment of ANS activity, the causality between ANS dysfunction and increased risk of new-onset AF can only be inferred. Future studies are needed to test the clinical management of AMI patients guided by HRV \[[@B20-jcm-09-01481]\].

The authors thank Theresa Daily and Suzanne Rankin for English revision of the paper, Florence Bichat, Morgane Laine and Aline Chagon for technical assistance.

Conceptualization, C.G.; Data curation, A.S. and M.M.; Formal analysis, M.M.; Investigation, A.S. and F.G.; Methodology, B.M. and M.M.; Supervision, C.G., D.M., L.L., Y.C. and M.Z.; Validation, B.M. and M.F.; Writing---original draft, A.S.; Writing---review & editing, C.G., M.F. and M.Z. All authors have read and agreed to the published version of the manuscript.

This study was supported by the University Hospital of Dijon, the Association de Cardiologie de Bourgogne and by grants from the Agence Régionale de Santé (ARS) de Bourgogne Franche-Comté, French Ministry of Research, Institut National de la Santé et de la Recherche Médicale (INSERM), Fédération Française de Cardiologie, Société Française de Cardiologie and from the Conseil Regional de Bourgogne Franche-Comté.

The authors declare no conflict of interest.

![Study Flow Chart.](jcm-09-01481-g001){#jcm-09-01481-f001}

![ROC curve demonstrating the predictive performance of LF/HF ratio for the onset of new AF during AMI: AUC = 0.73 (0.69--0.78; *p* \< 0.001); optimal threshold: 1.735; sensitivity = 0.698; specificity = 0.707.](jcm-09-01481-g002){#jcm-09-01481-f002}

jcm-09-01481-t001_Table 1

###### 

Patient Baseline Characteristics (n (%) or median (interquartile range).

  ------------------------------------------------------------------------------------
                                    No AF\              AF\                  *p*
                                    N = 1872            N = 168              
  --------------------------------- ------------------- -------------------- ---------
  Risk factors                                                               

  Age. years                        64 (53--76)         77 (70--83)          \<0.001

  Female                            519 (28%)           63 (38%)             0.007

  BMI. kg/m^2^                      26 (24--29)         26 (23--28)          0.067

  Hypertension                      924 (49%)           114 (68%)            \<0.001

  Hypercholesterolemia              832 (44%)           73 (44%)             0.804

  Family history of CAD             503 (27%)           41 (24%)             0.489

  Diabetes                          388 (21%)           36 (21%)             0.830

  Smoking                           649 (35%)           25 (15%)             \<0.001

  CV history                                                                 

  CAD                               350 (19%)           40 (24%)             0.106

  Stroke                            99 (5%)             16 (10%)             0.023

  Chronic renal failure             67 (4%)             8 (5%)               0.435

  Clinical data on admission                                                 

  HR. beats/min                     76 (65--89)         89 (70--108)         \<0.001

  SBP                               140 (121--160)      130 (116--150)       \<0.001

  DBP                               80 (70--92)         80 (64--90)          0.019

  Heart failure (Killip \>1)        315 (17%)           59 (35%)             \<0.001

  Anterior wall location            677 (36%)           58 (35%)             0.671

  STEMI                             1075 (57%)          107 (64%)            0.115

  LVEF. %                           55 (45--61)         47 (40--56)          \<0.001

  LVEF \<40%                        224 (13%)           33 (21%)             0.004

  GRACE risk score                  138 (115--163)      179 (150--202)       \<0.001

  Time to admission. min            192 (105--450)      180 (106--373)       0.818

  ICU stay. days                    4 (3--5)            5 (3--8)             \<0.001

  Biological data on admission                                               

  Creatinine, μmol/l                87 (74--105)        98 (79--117)         \<0.001

  eGFR CKD, mL/min                  76.3 (58.8--91.6)   60.9 (45.6--74.8)    \<0.001

  Glycaemia. mmol/L                 7.00 (5.92--8.77)   7.92 (6.45--10.41)   \<0.001

  CRP ≥ 3 mg/L                      1064 (63%)          111 (76%)            0.003

  Troponin Ic peak, μg/L            18.5 (3.8--41.0)    20.5 (6.5--41.0)     0.204

  NT--proBNP, pg/mL                 542 (138--2177)     2450 (735--6915)     \<0.001

  Log NT--proBNP, pg/mL             2.73 (2.14--3.34)   3.39 (2.87--3.84)    \<0.001

  Chronic medication on admission                                            

  Amiodarone                        10 (1%)             5 (3%)               0.005

  ARB/ACE inhibitors                633 (34%)           76 (45%)             0.002

  Beta blockers                     463 (25%)           63 (38%)             \<0.001

  Diuretic                          408 (22%)           64 (38%)             \<0.001

  Antiplatelet                      206 (11%)           25 (15%)             0.129

  Aspirin                           360 (19%)           51 (30%)             0.001

  VKA                               28 (2%)             5 (3%)               0.187

  Statin                            463 (25%)           46 (27%)             0.447

  Acute medications \<48 h                                                   

  Amiodarone                        72 (4%)             58 (35%)             \<0.001

  ARB/ACE inhibitors                1413 (75%)          103 (61%)            \<0.001

  Beta blockers                     1508 (81%)          109 (65%)            \<0.001

  Statin                            1533 (82%)          121 (72%)            0.002
  ------------------------------------------------------------------------------------

ACE: angiotensin conversion enzyme; ARB: angiotensin receptor blockers; AF: atrial fibrillation; BMI: body mass index; CAD: Coronary artery disease; CRP: C--reactive protein; CK: creatine kinase; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; HR: heart rate; ICU: Intensive Care Unit; LVEF: left ventricular ejection fraction; LWM: low molecular weight; NT-proBNP: N-terminal pro brain natriuretic peptide. PAD: peripheral artery disease; SBP: systolic blood pressure; STEMI: ST segment elevation myocardial infarction; VKA: vitamin K antagonist.

jcm-09-01481-t002_Table 2

###### 

Acute myocardial infarction management (n (%)).

  ---------------------------------------------------------------------
                                     No AF\       AF\         *p*
                                     N = 1872     N = 168     
  ---------------------------------- ------------ ----------- ---------
  Invasive treatment                                          

  Coronary angiography               1782 (95%)   154 (92%)   0.047

  TIMI class on culprit artery       N = 1716     N = 150     0.308

  0                                  789 (46%)    76 (51%)    

  1                                  93 (5%)      7 (5%)      

  2                                  179 (11%)    20 (13%)    

  3                                  655 (38%)    47 (31%)    

  TIMI class on culprit artery \<2   882 (51%)    83 (55%)    0.355

  CABG                               71 (4%)      8 (5%)      0.533

  Medical treatment                                           

  Thrombolysis                       274 (15%)    24 (14%)    0.902

  Antiplatelet                       1632 (87%)   135 (80%)   0.013

  Aspirin                            1811 (97%)   155 (92%)   0.003

  Low molecular weight heparin       1238 (66%)   62 (37%)    \<0.001

  Unfractionated heparin             850 (45%)    116 (69%)   \<0.001

  Glycoprotein IIbIIIa inhibitors    798 (43%)    53 (32%)    0.005
  ---------------------------------------------------------------------

AF: atrial fibrillation; CABG: coronary artery byass graft surgery; PCI: percutaneous coronary intervention.

jcm-09-01481-t003_Table 3

###### 

Holter parameters according to the onset of new AF during AMI, n (%), median (interquartile range) or mean (± standard deviation).

  ----------------------------------------------------------------------------------------------
                                               No AF\              AF\                 *p*
                                               N = 1872            N = 168             
  -------------------------------------------- ------------------- ------------------- ---------
  Heart rate. beats/min                        66 (60--73)         73 (60--84)         \<0.001

  Premature Ventricular Contractions (/24 h)   11 (2--92)          70 (7--378)         \<0.001

  VT episode (/24 h)                           0 (0--0)/1 ± 22     0 (0--0)/4 ± 44     0.011

  pNN50. %                                     4 (1--11)           11 (2--36)          \<0.001

  rMSSD. ms                                    27 (19--41)         45 (24--108)        \<0.001

  SDNN. ms                                     83 (64--107)        90 (61--119)        0.123

  Power. ms^2^                                 1850 (925--3507)    2007 (1036--5171)   0.044

  LF/HF                                        2.75 (1.46--4.58)   0.88 (0.57--2.00)   \<0.001

  LF/HF \< 1.735                               532 (30%)           111 (75%)           \<0.001
  ----------------------------------------------------------------------------------------------

AF: atrial fibrillation; VT: ventricular tachycardia; pNN50: proportion derived by dividing NN50 (the number of interval differences of successive NN intervals greater than 50 ms) by the total number of NN intervals; rMSSD: root mean square of successive differences in NN intervals; SDNN: standard deviation of all intervals between adjacent QRS complexes resulting from sinus node depolarization; LF: low frequencies; HF: high frequencies.

jcm-09-01481-t004_Table 4

###### 

In-hospital outcomes according to the onset of new AF during AMI n (%).

  ---------------------------------------------------
                  No AF\       AF\          *p*
                  N = 1872     N = 168      
  --------------- ------------ ------------ ---------
  Death           21 (1.1%)    8 (4.8%)     0.002

  CV death        17 (0.9%)    6 (3.6%)     0.009

  Recurrent MI    89 (4.8%)    10 (6.0%)    0.489

  Heart Failure   417 (22%)    93 (55%)     \<0.001

  Stroke          19 (1.0%)    5 (3.0%)     0.042

  VT or VF        130 (6.9%)   29 (17.3%)   \<0.001
  ---------------------------------------------------

AF: atrial fibrillation; CV: cardio vascular; MI: myocardial infarction; VT: ventricular tachycardia; VF: ventricular fibrillation.

jcm-09-01481-t005_Table 5

###### 

Logistic regression analysis for the prediction of in-hospital AF.

                                 Univariate             Multivariable 1                              Multivariable 2                                                              
  ------------------------------ ---------------------- -------------------------------------------- ------------------------------------------- --------- ---------------------- ---------
  Female                         1.564 (1.126--2.172)   0.008                                        0.756 (0.501--1.140)                        0.182     0.671 (0.434--1.038)   0.073
  Age, Years                     1.063 (1.049--1.077)   \<0.001                                      1.049 (1.028--1.071)                        \<0.001   1.036 (1.01--1.060)    0.002
  Hypertension                   2.166 (1.547--3.032)   \<0.001                                      1.160 (0.734--1.834)                        0.525     1.234 (0.756--2.014)   0.400
  Smoker                         0.329 (0.213--0.509)   \<0.001                                      0.996 (0.561--1.766)                        0.988     1.078 (0.586--1.980)   0.810
  Previous Stroke                1.885 (1.084--3.279)   0.025                                        0.994 (0.513--1.926)                        0.986     0.949 (0.484--1.862)   0.879
  HR (holter), bpm               1.043 (1.031--1.055)   \<0.001                                      1.039 (1.025--1.054)                        \<0.001   1.034 (1.019--1.048)   \<0.001
  CRP \>3 mg/L                   1.785 (1.210--2.633)   0.003                                        1.189 (0.741--1.910)                        0.473     1.199 (0.722--1.992)   0.482
  eGFR CKD, mL/min               0.975 (0.969--0.981)   \<0.001                                      0.997 (0.987--1.008)                        0.616     0.998 (0.987--1.008)   0.659
  NT--proBNP (log)               2.687 (2.143--3.369)   \<0.001                                      1.479 (1.100--1.990)                        0.010     1.379 (1.001--1.899)   0.049
  Glycemia, mmol/L               1.000 (0.995--1.005)   0.998                                        X                                                     X                      
  Troponin I Peak, µg/L          1.001 (0.997--1.004)   0.699                                        X                                                     X                      
  Beta Blockers (Chronic)        1.826 (1.313--2.539)   \<0.001                                      1.067 (0.701--1.624)                        0.763     0.950 (0.604--1.493)   0.823
  ARB/ACE Inhibitors (Chronic)   1.680 (1.222--2.311)   0.001                                        0.921 (0.601--1.411)                        0.704     0.866 (0.550--1.361)   0.532
  LF/HF \<1.735                  6.748 (4.605--9.889)   \<0.001                                      X                                                     3.377 (2.047--5.572)   \<0.001
  Quality Indexes                                       Phl = 0.324; −2LL = 796.132; %class = 92.5   pHL = 0.106;−2LL = 706.701; %class = 92.8                                    

ACE: angiotensin conversion enzyme; ARB: angiotensin receptor blockers; CRP: C-reactive protein; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; HR: heart rate.

[^1]: These authors contributed equally to this work.
